Grave Concerns Resulting from Court Decision to Suspend Abortion Pill Approval and Access
MichBio, like many other stakeholders in the life sciences industry, has serious concerns over the recent Texas Court decision to suspend the FDA approval of abortion pill mifepristone and what it may mean more broadly for the FDA’s ability to regulate drug reviews and approval. The decision, should it stand upon appeal, would set a very dangerous precedent.
MichBio joined many across the bio-industry ecosystem in a scorching letter that warned the court order, if allowed to take effect would thwart F.D.A.’s scientific judgment and completely upend their statutory authority. In addition and subsequently, the Association threw its support to amici briefs submitted to the U.S. Supreme Court and the 5th Circuit Court of Appeals, as the legal process evolves.